期刊
NUCLEAR MEDICINE COMMUNICATIONS
卷 34, 期 2, 页码 98-107出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MNM.0b013e32835bd59d
关键词
In-111-pentetreotide; I-123-MIBG; I-131-MIBG therapy; F-18-DOPA; Ga-68-DOTA-TATE; metaiodobenzylguanidine scintigraphy; peptide receptor radionuclide therapy; positron emission tomography/computed tomography; somatostatin receptor scintigraphy
The scintigraphic investigation of neuroendocrine tumours such as carcinoids has depended on standard techniques such as I-123-metaiodobenzylguanidine and In-111-pentetreotide imaging. More recently, the use of PET techniques such as Ga-68-DOTATATE has been advocated. An alternative improved modality is high-quality single photon emission computed tomography/computed tomography (SPECT/CT), which has the advantages of better sensitivity and specificity and has shown improved localization in up to 60% of cases. These advantages are especially true for pancreatic and lymph node lesions. Overall, SPECT/CT can result in a change in clinical management in 25% of patients. Although it is possible to combine SPECT and CT performed at different time points, there is better anatomical localization and improved reporter confidence when SPECT and CT are performed simultaneously. Nucl Med Commun 34:98-107 (C) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据